A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)

Prostate Cancer Metastatic Clinical Trial

Official title:

A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04660617
• Other study ID #: MOSMPCA
• Status: Not yet recruiting
• Start date: August 1, 2021
• Est. completion date: April 1, 2023

Study information

• Verified date: May 2021
• Source: West China Hospital
• Contact: Jinge Zhao, Dr.
• Phone: 86 13679017572
• Email: jingezhao[@]foxmail.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The investigators plan to perform multi-omics technologies, including genomic, transcriptomic, epigenomic and proteomic methods, in patients with metastatic prostate cancer, aiming at uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets.

Description:

Prostate cancer is the commonest malignancy and the second leading cause of tumor-related death among males worldwide. Though patients with early stage prostate cancer can obtain satisfactory therapeutic efficacy from radical prostatectomy or radiotherapy, the prognosis of men with metastatic prostate cancer (mPCa), especially metastatic castration-resistant prostate cancer (mCRPC), is still poor. Recent years have witnessed the rapid development of the high-throughput technologies, including genomic, transcriptomic, epigenomic and proteomic methods. These techniques are promising in uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets. In the current prospective study, the investigators plan to perform multi-omics technologies in patients with mPCa, aiming at uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: April 1, 2023
• Est. primary completion date: November 1, 2022
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Pathological confirmation of prostate cancer
• Age: =40 years old
• Bone or visceral metastatic disease confirmed by image examination.
• Written informed consent

Exclusion Criteria:

• Patients harbouring other types of cancer besides prostate cancer

Related Conditions & MeSH terms

• Prostate Cancer Metastatic
• Prostatic Neoplasms

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
West China Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Genetic profiling results	Mutation identified via whole-genome sequencing will be recored.	From baseline (initial diagnosis of PCa), until study completion (48 months)
Primary	Transcriptional profiling results	Determining the transcriptomic information of metastatic prostate cancer by performing whole transcriptome sequencing	From baseline (initial diagnosis of PCa), until study completion (48 months)
Primary	Epigenomic profiling results	Determining the epigenomic status of specific genes by performing DNA-methylation sequencing	From baseline (initial diagnosis of PCa), until study completion (48 months)
Secondary	Protein expression results	Determing the expression status of centain proteins by performing immunohistochemistry in prostate biopsy specimen	From baseline (initial diagnosis of PCa), until study completion (48 months)